1. Search Result
Search Result
Results for "

IGF1R

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

10

Inhibitory Antibodies

5

Natural
Products

9

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145110

    IGF-1R Cancer
    IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis [1].
    IGF-1R inhibitor-2
  • HY-156914

    IGF-1R Src Cancer
    IGF-1R/SRC-IN-1 (Compound 3b) is an inhibitor for IGF-1R (IC50 is 63 μM) and SRC [1].
    IGF-1R/SRC-IN-1
  • HY-15609
    AZD-3463
    1 Publications Verification

    ALK/IGF1R inhibitor

    IGF-1R Anaplastic lymphoma kinase (ALK) Autophagy Apoptosis Endocrinology Cancer
    AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells [1] .
    AZD-3463
  • HY-169572

    IGF-1R Cancer
    IGF-1R inhibitor-5 (compound 19) is a potent inhibitor of IGF-1R, with the IC50 of 6 μM. IGF-1R inhibitor-5 has the potential for the research of cancer [1].
    IGF-1R inhibitor-5
  • HY-169600

    IGF-1R Cancer
    IGF-1R inhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, with the inhibitiron rate of 63% at 10 μM. IGF-1R inhibitor-4 plays an important role in cancer research [1].
    IGF-1R inhibitor-4
  • HY-162506

    IGF-1R Cancer
    IGF-1R inhibitor-3 (Compound C11) is an allosteric inhibitor for insulin-like growth factor receptor 1 kinase (IGF-1R), with an IC50 of 0.2 μM [1].
    IGF-1R inhibitor-3
  • HY-402309

    IGF-1R EGFR Trk Receptor Neurological Disease
    IGF-1R modulator 1 (Example 5) is an IGF-1R modulator, with EC50s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease [1].
    IGF-1R modulator 1
  • HY-RS06615

    Small Interfering RNA (siRNA) Others

    IGF1R Human Pre-designed siRNA Set A contains three designed siRNAs for IGF1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IGF1R Human Pre-designed siRNA Set A
    IGF1R Human Pre-designed siRNA Set A
  • HY-RS06616

    Small Interfering RNA (siRNA) Others

    Igf1r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Igf1r Mouse Pre-designed siRNA Set A
    Igf1r Mouse Pre-designed siRNA Set A
  • HY-RS06617

    Small Interfering RNA (siRNA) Others

    Igf1r Rat Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Igf1r Rat Pre-designed siRNA Set A
    Igf1r Rat Pre-designed siRNA Set A
  • HY-P99294

    AMG 479; Human Anti-IGF1R Recombinant Antibody

    IGF-1R Cancer
    Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer [1].
    Ganitumab
  • HY-P99197

    CP-751871

    IGF-1R Cancer
    Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM [1].
    Figitumumab
  • HY-N0908
    Ginsenoside Rg5
    2 Publications Verification

    IGF-1R NF-κB COX Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.
    Ginsenoside Rg5
  • HY-10253
    AG1024
    5+ Cited Publications

    Tyrphostin AG 1024

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective IGF-1R inhibitor with an IC50 of 7 μM. AG1024 inhibits phosphorylation of IR (IC50=57 μM). AG1024 induces apoptosis and has anti-cancer activity [1] .
    AG1024
  • HY-18785

    IGF-1R Endocrinology Cancer
    Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R.
    Indirubin Derivative E804
  • HY-P99672

    MM 141; MM-005

    IGF-1R EGFR Cancer
    Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers [1] .
    Istiratumab
  • HY-N0908R

    IGF-1R NF-κB COX Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ginsenoside Rg5 (Standard) is the analytical standard of Ginsenoside Rg5. This product is intended for research and analytical applications. Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.
    Ginsenoside Rg5 (Standard)
  • HY-P3226

    IGF-1R Metabolic Disease
    JB-1, an IGF-1 peptide analog, is a selective and potent IGF-1R antagonist. JB-1 competes with IGF-1 by binding the IGF-1 receptor. JB-1 prevents the autophosphorylation of IGF-1R, and has no activity in IGF-II [1].
    JB-1
  • HY-15494
    Picropodophyllin
    20+ Cited Publications

    AXL1717; Picropodophyllotoxin; PPP

    IGF-1R Apoptosis Endocrinology Cancer
    Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin
  • HY-125102

    IGF-1R Cancer
    AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.
    AZ12253801
  • HY-P99165
    Teprotumumab
    1 Publications Verification

    IGF-1R TSH Receptor Endocrinology
    Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research [1].
    Teprotumumab
  • HY-14357

    IGF-1R Cancer
    BMS 695735 (compound 10) is an inhibitor of IGF-1R with an IC50 value of 0.034 μM. BMS 695735 has anti-tumor activity [1].
    BMS 695735
  • HY-P99284
    Dalotuzumab
    1 Publications Verification

    MK-0646; h7C10

    IGF-1R Apoptosis Cancer
    Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo [1] .
    Dalotuzumab
  • HY-B0794A

    EGFR IGF-1R Drug Metabolite Endocrinology Cancer
    AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550 hydrochloride
  • HY-B0794B
    AZ7550 Mesylate
    3 Publications Verification

    AZ7550 trimesylate salt

    EGFR IGF-1R Drug Metabolite Endocrinology Cancer
    AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550 Mesylate
  • HY-B0794

    EGFR IGF-1R Drug Metabolite Endocrinology Cancer
    AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550
  • HY-15749
    XL228
    3 Publications Verification

    Aurora Kinase Bcr-Abl IGF-1R Src Endocrinology Cancer
    XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
    XL228
  • HY-15494S1

    AXL1717-d6; Picropodophyllotoxin-d6; PPP-d6

    Isotope-Labeled Compounds IGF-1R Apoptosis Endocrinology Cancer
    Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin-d6
  • HY-10262
    BMS-536924
    4 Publications Verification

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity [1] .
    BMS-536924
  • HY-P99218

    Sch 717454; 19D12

    IGF-1R Cancer
    Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research [1] .
    Robatumumab
  • HY-P990084

    IGF-1R Cancer
    Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody [1].
    Veligrotug
  • HY-N6611

    IGF-1R Infection Inflammation/Immunology Cancer
    Chimaphilin is an IGF-1R inhibitor (IC50: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola [1] .
    Chimaphilin
  • HY-50866
    NVP-AEW541
    5+ Cited Publications

    AEW541

    IGF-1R Insulin Receptor Autophagy Endocrinology Cancer
    NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity [1].
    NVP-AEW541
  • HY-13203
    NVP-TAE 226
    5+ Cited Publications

    TAE226

    FAK Pyk2 IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively [1] .
    NVP-TAE 226
  • HY-15656
    Ceritinib
    Maximum Cited Publications
    30 Publications Verification

    LDK378

    Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Endocrinology Cancer
    Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency [1] .
    Ceritinib
  • HY-15656A
    Ceritinib dihydrochloride
    Maximum Cited Publications
    30 Publications Verification

    LDK378 dihydrochloride

    Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Endocrinology Cancer
    Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride (LDK378 dihydrochloride) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride (LDK378 dihydrochloride) shows great antitumor potency [1] .
    Ceritinib dihydrochloride
  • HY-50866B

    AEW541 dihydrochloride

    IGF-1R Insulin Receptor Autophagy Cancer
    NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity [1].
    NVP-AEW541 dihydrochloride
  • HY-108230

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities [1].
    ALK-IN-12
  • HY-10252
    NVP-ADW742
    2 Publications Verification

    ADW742; GSK 552602A; ADW

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells [1] .
    NVP-ADW742
  • HY-P5438

    Btk c-Kit FAK FLT3 Insulin Receptor Others
    Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
    Srctide
  • HY-10524
    GSK1904529A
    5+ Cited Publications

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity [1] .
    GSK1904529A
  • HY-15656R

    Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Endocrinology Cancer
    Ceritinib (Standard) is the analytical standard of Ceritinib. This product is intended for research and analytical applications. Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency [1] .
    Ceritinib (Standard)
  • HY-13326
    ASP3026
    5 Publications Verification

    Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK Cancer
    ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research [1] .
    ASP3026
  • HY-116624
    MAZ51
    4 Publications Verification

    VEGFR Apoptosis Cancer
    MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity [1] .
    MAZ51
  • HY-21291

    PDGFR EGFR IGF-1R Cancer
    SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation [1].
    SU-4313
  • HY-118046

    G Protein-coupled Receptor Kinase (GRK) ROCK IGF-1R Cardiovascular Disease
    GSK2163632A is a selective G protein-coupled receptor kinase (GRK) inhibitor that can be used as a probe for studying heart failure and Parkinson's disease. GSK2163632A potently inhibits GRK1 and GRK5, and also inhibits Rho-associated coiled-coil kinase (ROCK) and insulin-like growth factor receptor IGF-1R. GSK2163632A binds to GRK2 in a manner similar to Paroxetine (HY-122272).
    GSK2163632A
  • HY-135680

    I-OMe-AG 538

    IGF-1R Metabolic Disease Cancer
    I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50?of 1 μM [1].
    I-OMe-Tyrphostin AG 538
  • HY-100349

    PDGFR VEGFR Cancer
    SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively [1].
    SU4312
  • HY-B0794S

    EGFR IGF-1R Drug Metabolite Others
    AZ7550-d5 is the deuterium labeled AZ7550 (HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of IGF1R with an IC50 of 1.6 μM[1][2].
    AZ7550-d5
  • HY-168616

    RSV IGF-1R Infection
    CL-A3-7 is a virus-cell fusion inhibitor targeting the RSV F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type RSV and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research [1].
    CL-A3-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: